^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Basal Cell Carcinoma
    Drug:Libtayo (cemiplimab-rwlc) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Sanofi Press Release
    Title:

    Libtayo® (cemiplimab) approved in Canada for locally advanced basal cell carcinoma (BCC) patients

    Published date:
    10/29/2021
    Excerpt:
    Libtayo® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a hedgehog pathway inhibitor (HHI).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Regeneron Pharmaceuticals Press Release
    Title:

    LIBTAYO® (CEMIPLIMAB) APPROVED BY THE EUROPEAN COMMISSION AS THE FIRST IMMUNOTHERAPY INDICATED FOR PATIENTS WITH ADVANCED BASAL CELL CARCINOMA

    Published date:
    06/25/2021
    Excerpt:
    Regeneron Pharmaceuticals, Inc...and Sanofi today announced that the European Commission (EC) has approved the PD-1 inhibitor Libtayo® (cemiplimab) to treat adults with locally advanced or metastatic basal cell carcinoma (BCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    02/09/2021
    Excerpt:
    LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated:...for the treatment of patients with locally advanced BCC (laBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate...for the treatment of patients with metastatic BCC (mBCC) previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Locally advacned (LaBCC) and Metastatic Basal cell skin cancer (mBCC): Cemiplimab-rwlc for patients with locally advanced or mBCC previously treated with a hedgehog pathway inhibitor [HHI] or for whom an HHI is not appropriate.